You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Subconjunctival Bevacizumab Injection for Corneal Neovascularization

Bahar, Irit MD; Kaiserman, Igor MD, MSc, MHA; McAllum, Penny MBChB, FRANZCO; Rootman, David MD, FRCSC; Slomovic, Allan MA, MD, FRCSC

doi: 10.1097/ICO.0b013e318159019f
Clinical Science

Purpose: To report on the clinical use of subconjunctival bevacizumab in patients with corneal neovascularization.

Methods: The charts of 10 consecutive patients with corneal neovascularization who received subconjunctival injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Digital photographs of the cornea were graded by 2 masked observers for density, extent, and centricity of corneal vascularization. Image analysis was used to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.

Results: No significant ocular or systemic adverse events were observed during 3.5 ± 1.1 months of follow-up. Seven patients showed partial regression of vessels. The extent decreased from 6.0 ± 1.2 (SD) clock hours before the injection to 4.6 ± 1.0 clock hours after bevacizumab injection (P = 0.008). Density decreased from 2.7 ± 0.2 to 1.9 ± 0.3, respectively. (P = 0.007). No change was noticed in the centricity of corneal vessels. Corneal neovascularization covered, on average, 14.8% ± 2.5% (SD) of the corneal surface before the injections, compared with 10.5% ± 2.8% (P = 0.36, t test) after bevacizumab injection. Therefore, bevacizumab decreased corneal neovascularization by 29%.

Conclusions: Short-term results suggest that subconjunctival bevacizumab is well tolerated and associated with a partial regression of corneal neovascularization.

Author Information

From the Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.

Received for publication June 23, 2007; revision received August 15, 2007; accepted August 16, 2007.

Reprints: Irit Bahar, MD, Department of Ophthalmology, Toronto Western Hospital, 399 Bathurst Street, Ontario, Canada M5T2S8 (e-mail:

Copyright © 2008 Wolters Kluwer Health, Inc. All rights reserved.